{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:42:48Z","timestamp":1791193368200,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T00:00:00Z","timestamp":1392940800000},"content-version":"vor","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemistry & Biology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.chembiol.2012.12.006","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T14:54:36Z","timestamp":1361458476000},"page":"146-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":640,"title":["Developing Irreversible Inhibitors of the Protein Kinase Cysteinome"],"prefix":"10.1016","volume":"20","author":[{"given":"Qingsong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Sabnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara\u00a0J.","family":"Buhrlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn\u00a0H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael\u00a0S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2012.12.006_bib1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jnr.10773","article-title":"Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells","volume":"74","author":"Bansal","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.chembiol.2012.12.006_bib2","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: balancing the benefits and risks","volume":"55","author":"Barf","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib3","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cbic.201000205","article-title":"In\u00a0vivo\u00a0efficacy of natural product-inspired irreversible kinase inhibitors","volume":"11","author":"Barluenga","year":"2010","journal-title":"ChemBioChem"},{"key":"10.1016\/j.chembiol.2012.12.006_bib4","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1074\/jbc.M511878200","article-title":"Binding of manumycin A inhibits IkappaB kinase beta activity","volume":"281","author":"Bernier","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/1471-2105-8-381","article-title":"PFAAT version 2.0: a tool for editing, annotating, and analyzing multiple sequence alignments","volume":"8","author":"Caffrey","year":"2007","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.chembiol.2012.12.006_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/asia.200800427","article-title":"Chemical modification of proteins at cysteine: opportunities in chemistry and biology","volume":"4","author":"Chalker","year":"2009","journal-title":"Chem. Asian J."},{"key":"10.1016\/j.chembiol.2012.12.006_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3410\/B3-19","article-title":"Conformational selection or induced fit? 50 years of debate resolved","volume":"3","author":"Changeux","year":"2011","journal-title":"F1000 Biol. Rep."},{"key":"10.1016\/j.chembiol.2012.12.006_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science1108367","article-title":"Structural bioinformatics-based design of selective, irreversible kinase inhibitors","volume":"308","author":"Cohen","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2012.12.006_bib9","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1038\/ncb0502-e127","article-title":"The origins of protein phosphorylation","volume":"4","author":"Cohen","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"Cowan-Jacob","year":"2007","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.chembiol.2012.12.006_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib12","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2012.12.006_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib14","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1073\/pnas.95.20.12022","article-title":"Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor","volume":"95","author":"Fry","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2012.12.006_bib15","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2174\/092986711796391705","article-title":"Irreversible protein kinase inhibitors","volume":"18","author":"Garuti","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/jpet.109.156554","volume":"331","author":"Goto","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.chembiol.2012.12.006_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cell.2011.03.026","article-title":"The evolving war on cancer","volume":"145","author":"Haber","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2012.12.006_bib18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2012.12.006_bib19","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1021\/jm200222m","article-title":"Irreversible Nek2 kinase inhibitors with cellular activity","volume":"54","author":"Henise","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/138945010790711996","article-title":"Halogen atoms in the modern medicinal chemistry: hints for the drug design","volume":"11","author":"Hernandes","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.chembiol.2012.12.006_bib21","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2012.12.006_bib22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1073\/pnas.77.3.1311","article-title":"Transforming gene product of Rous sarcoma virus phosphorylates tyrosine","volume":"77","author":"Hunter","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2012.12.006_bib23","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1016\/j.bmcl.2008.07.062","article-title":"Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase","volume":"18","author":"Hur","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.chembiol.2012.12.006_bib24","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/tx200342b","article-title":"Control of oxidative posttranslational cysteine modifications: from intricate chemistry to widespread biological and medical applications","volume":"25","author":"Jacob","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib25","doi-asserted-by":"crossref","first-page":"11498","DOI":"10.1002\/chem.200901375","article-title":"Synthesis of a resorcylic acid lactone (RAL) library using fluorous-mixture synthesis and profile of its selectivity against a panel of kinases","volume":"15","author":"Jogireddy","year":"2009","journal-title":"Chemistry"},{"key":"10.1016\/j.chembiol.2012.12.006_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4155\/fmc.10.21","article-title":"Strategies for discovering and derisking covalent, irreversible enzyme inhibitors","volume":"2","author":"Johnson","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3410\/M4-5","article-title":"Kinase inhibitors in the treatment of immune-mediated disease","volume":"4","author":"Kontzias","year":"2012","journal-title":"F1000. Med-Rep."},{"key":"10.1016\/j.chembiol.2012.12.006_bib29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1074-5521(01)00049-7","article-title":"The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase","volume":"8","author":"Kwok","year":"2001","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1177\/1087057109339207","article-title":"Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform","volume":"14","author":"Lebakken","year":"2009","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.chembiol.2012.12.006_bib31","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bcp.2006.08.014","article-title":"Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid","volume":"72","author":"Lee","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib32","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1002\/anie.201007871","article-title":"Redox-based probes for protein tyrosine phosphatases","volume":"50","author":"Leonard","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.chembiol.2012.12.006_bib33","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm101396q","article-title":"Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors","volume":"54","author":"Leproult","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib34","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.chembiol.2012.12.006_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1039\/c2np00097k","article-title":"Natural products as kinase inhibitors","volume":"29","author":"Liu","year":"2012","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.chembiol.2012.12.006_bib37","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1074\/jbc.M111.304485","article-title":"Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0968-0004(02)02179-5","article-title":"Evolution of protein kinase signaling from yeast to man","volume":"27","author":"Manning","year":"2002","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.chembiol.2012.12.006_bib39","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2012.12.006_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.110.168583","volume":"335","author":"Muramoto","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.chembiol.2012.12.006_bib41","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.109.027797","article-title":"A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding","volume":"37","author":"Nakayama","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.chembiol.2012.12.006_bib42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bbrc.2006.12.083","article-title":"Role of a cysteine residue in the active site of ERK and the MAPKK family","volume":"353","author":"Ohori","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.chembiol.2012.12.006_bib43","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1073\/pnas.0501205102","article-title":"High-resolution functional proteomics by active-site peptide profiling","volume":"102","author":"Okerberg","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2012.12.006_bib44","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1021\/bi062142x","article-title":"Functional interrogation of the kinome using nucleotide acyl phosphates","volume":"46","author":"Patricelli","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.chembiol.2012.12.006_bib45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chembiol.2011.04.011","article-title":"In situ kinase profiling reveals functionally relevant properties of native kinases","volume":"18","author":"Patricelli","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib46","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1016\/j.bmc.2009.08.042","article-title":"Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools","volume":"17","author":"Perez","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib47","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/jm8008597","article-title":"Covalent modifiers: an orthogonal approach to drug design","volume":"52","author":"Potashman","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib48","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chembiol.2012.12.006_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/47520","article-title":"Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase","volume":"403","author":"Rossi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2012.12.006_bib50","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in\u00a0vitro and in\u00a0vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.chembiol.2012.12.006_bib51","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1073\/pnas.0600445103","article-title":"Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides","volume":"103","author":"Schirmer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2012.12.006_bib52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib53","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/jm960380s","article-title":"Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases","volume":"40","author":"Singh","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib54","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","article-title":"Targeted covalent drugs of the kinase family","volume":"14","author":"Singh","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2012.12.006_bib56","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/jm990482t","article-title":"Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions","volume":"43","author":"Smaill","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib57","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/jm800498e","article-title":"Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins","volume":"52","author":"Smith","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0024-3205(99)00259-3","article-title":"Suppression of oncogenic transformation by hypothemycin associated with accelerated cyclin D1 degradation through ubiquitin-proteasome pathway","volume":"65","author":"Sonoda","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.chembiol.2012.12.006_bib59","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chembiol.2012.12.006_bib60","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/jm040159c","article-title":"Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity","volume":"48","author":"Tsou","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: past, present, and future","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(24)39230-4","article-title":"SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence","volume":"293","author":"Underwood","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.chembiol.2012.12.006_bib63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1039\/B610344H","article-title":"Chemistry and biology of resorcylic acid lactones","author":"Winssinger","year":"2007","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.chembiol.2012.12.006_bib64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ardp.200800009","article-title":"The development of HKI-272 and related compounds for the treatment of cancer","volume":"341","author":"Wissner","year":"2008","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.chembiol.2012.12.006_bib65","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1021\/jm050559f","article-title":"2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2","volume":"48","author":"Wissner","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib66","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1016\/j.bmc.2007.03.055","article-title":"Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2","volume":"15","author":"Wissner","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib67","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1158\/1535-7163.MCT-08-0263","article-title":"17-Acetoxyjolkinolide B irreversibly inhibits IkappaB kinase and induces apoptosis of tumor cells","volume":"7","author":"Yan","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.chembiol.2012.12.006_bib68","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.lungcan.2005.10.006","article-title":"EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib","volume":"51","author":"Yoshimura","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.chembiol.2012.12.006_bib69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2012.12.006_bib70","doi-asserted-by":"crossref","first-page":"10047","DOI":"10.1021\/jm301190s","article-title":"Covalent inhibitors of interleukin-2 inducible T\u00a0cell kinase (itk) with nanomolar potency in a whole-blood assay","volume":"55","author":"Zapf","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2012.12.006_bib71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.chembiol.2012.12.006_bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.chembiol.2011.11.010","article-title":"Discovery of potent and selective covalent inhibitors of JNK","volume":"19","author":"Zhang","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2012.12.006_bib73","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2012.12.006_bib74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2010.02.007","article-title":"A structure-guided approach to creating covalent FGFR inhibitors","volume":"17","author":"Zhou","year":"2010","journal-title":"Chem. Biol."}],"container-title":["Chemistry & Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074552112004875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074552112004875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T07:20:09Z","timestamp":1761031209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074552112004875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1074552112004875"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2012.12.006","relation":{},"ISSN":["1074-5521"],"issn-type":[{"value":"1074-5521","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing Irreversible Inhibitors of the Protein Kinase Cysteinome","name":"articletitle","label":"Article Title"},{"value":"Chemistry & Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2012.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}